PTGX - Omeros Anavex Results Positive Protagonist Suffers Setback: The Good Bad And Ugly Of Biopharma
Omeros (OMER) reported positive results for OMS721 or narsoplimab, an anti-MASP-2 antibody that Omeros plans to use in HSCT-associated thrombotic microangiopathy, or HSCT-TMA, a potentially fatal complication of using stem cells to treat hematological malignancies. The treatment achieved 100 days survival for 65 percent of the patients in the trial. An HSCT physician quoted by Omeros said the typical 100-day survival rate is less than 20%. Other key assessments of the trial were as follows:
Primary efficacy endpoint
- 56 percent of all patients receiving at least one dose of narsoplimab achieved complete responder status (met